Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors
暂无分享,去创建一个
J. Moul | S. Srivastava | A. Heidenreich | J.W. Moul | R. Hofmann | A. Heidenreich | S. Srivastava | R. Hofmann
[1] T. Strohmeyer,et al. Glutathione S-transferases in human testicular germ cell tumors: changes of expression and activity. , 1992, The Journal of urology.
[2] T. Furuchi,et al. Inhibition of testicular germ cell apoptosis and differentiation in mice misexpressing Bcl-2 in spermatogonia. , 1996, Development.
[3] C. Chresta,et al. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. , 1996, Cancer research.
[4] A. Fraioli,et al. Stone Recurrence after Lithotripsy in Patients with Recurrent Idiopathic Calcium Urolithiasis: Efficacy of Treatment with Fiuggi Water , 2000, European Urology.
[5] T. Miki,et al. Altered imprinting of the H19 and insulin-like growth factor II genes in testicular tumors. , 1997, The Journal of urology.
[6] R. Lothe,et al. Molecular genetic changes in human male germ cell tumors. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[7] G. Viglietto,et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. , 1996, Oncogene.
[8] J. Moul,et al. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. , 1995, The Journal of urology.
[9] G. Sledge,et al. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. , 1994, Cancer research.
[10] R. Fimmers,et al. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. , 1998, Cancer.
[11] Y. Tsujimoto,et al. Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.
[12] I. Damjanov. Pathogenesis of testicular germ cell tumours. , 1993, European urology.
[13] J. M. Lee,et al. p53 mutations increase resistance to ionizing radiation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[14] D. Slamon,et al. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. , 1995, The Journal of urology.
[15] R. Tarone,et al. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. , 1988, Carcinogenesis.
[16] N. Skakkebaek,et al. Possible carcinoma-in-situ of the testis. , 1972, Lancet.
[17] B. Gallie,et al. Mutations of the p53 gene do not occur in testis cancer. , 1993, Cancer research.
[18] T. Strohmeyer,et al. FAULTY CELL CYCLE RESTRICTION POINT G1/S IN HUMAN TESTICULAR TUMORS: DEREGULATION OF E2F-1, CYCLIN DEPENDENT KINASE 2 (CDK2) and CYCLIN D2 GENE EXPRESSION , 1999 .
[19] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[20] E. Mumperow,et al. Spermatic Cord β-Human Chorionic Gonadotropin Levels in Seminoma and their Clinical Implications , 1992 .
[21] L. Looijenga,et al. Interphase cytogenetics of carcinoma in situ of the testis. Numeric analysis of the chromosomes 1, 12 and 15. , 1993, European urology.
[22] J. Moul,et al. Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization , 1992, Genes, chromosomes & cancer.
[23] J. Moul,et al. Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. , 1993, The Journal of urology.
[24] L. Liotta,et al. Molecular aspects of tumor cell invasion and metastasis , 1993, Cancer.
[25] J. Moul,et al. Prognostic factors in low-stage nonseminomatous testicular cancer. , 1996, Oncology.
[26] C. Cordon-Cardo,et al. Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Levine,et al. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[28] T. Ulbright,et al. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage a nonseminomatous testicular germ cell tumor at low risk for occult metastasis , 1995, Cancer.
[29] J. Bartek,et al. p53 Protein alterations in human testicular cancer including pre‐invasive intratubular germ‐cell neoplasia , 1991, International journal of cancer.
[30] C. Catton,et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. , 1997, The Journal of urology.
[31] Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. , 1996, The Journal of urology.
[32] D. Bishop,et al. Candidate regions for testicular cancer susceptibility genes , 1998, Human molecular genetics.
[33] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[34] T. Strohmeyer,et al. Alterations of the metastasis suppressor gene nm23 and the proto-oncogene c-myc in human testicular germ cell tumors. , 1997, The Journal of urology.
[35] K. Dieckmann,et al. Immunohistological determination of proliferative activity in seminomas. , 1988, Journal of Clinical Pathology.
[36] F. Mostofi,et al. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis , 1998, Cancer.
[37] E. Mariman,et al. Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. , 1994, Journal of the National Cancer Institute.
[38] J. Serth,et al. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis , 1996, Cancer.
[39] I. Shaw. Detection of the c-myc oncogene product in testicular cancer. , 1985, British Journal of Cancer.
[40] S. Melmed,et al. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. , 1995, The Journal of urology.
[41] T. Miki,et al. Doppler Resistive Index in Benign Prostatic Hyperplasia: Correlation with Ultrasonic Appearance of the Prostate and Infravesical Obstruction , 2000, European Urology.
[42] P. Goss,et al. Loss of heterozygosity of tumor suppressor genes in testis cancer. , 1995, Cancer research.
[43] P. Albers,et al. Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors , 1994, Cancer.
[44] J. Moul,et al. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl‐2 oncogene in primary testicular germ cell tumours , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[45] J. Moul,et al. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. , 1998, The Journal of urology.
[46] D. Slamon,et al. Expression of p21 ras oncoproteins in human cancers. , 1986, Cancer research.
[47] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[48] A. Heidenreich,et al. Screening, Diagnostik und Therapie der testikulären intraepithelialen Neoplasie (TIN) , 1995 .
[49] L. Liotta,et al. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.
[50] J. Stewart,et al. The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. , 1986, British Journal of Cancer.
[51] R. Chaganti,et al. Cytogenetics of male germ-cell tumors. , 1993, The Urologic clinics of North America.
[52] V. Reuter,et al. Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[53] A. Ullrich,et al. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. , 1991, Cancer research.
[54] J. Moul,et al. MOLECULAR ANALYSIS OF P16Ink4/CDKN2 AND P15Ink4B/MTS2 GENES IN PRIMARY HUMAN TESTICULAR GERM CELL TUMORS , 1998 .
[55] Y. Nakamura,et al. Loss of 3p or 11p alleles is associated with testicular cancer tumors. , 1989, Genomics.
[56] F. Mostofi,et al. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. , 1997, The Journal of urology.
[57] V. Reuter,et al. Detection of preferential NRAS mutations in human male germ cell tumors by the polymerase chain reaction , 1990, Genes, chromosomes & cancer.
[58] B. Tycko. Genomic imprinting: mechanism and role in human pathology. , 1994, The American journal of pathology.
[59] J. Oosterhuis,et al. Cytogenetics of carcinoma in situ of the testis. , 1990, Cancer genetics and cytogenetics.
[60] J. Moul,et al. Prognostic risk factors in low stage testicular germ cell tumors , 1997, Cancer.
[61] D. Forman,et al. Candidate regions for a testicular cancer susceptibility gene , 1995 .
[62] D. Slamon,et al. Mutations of the p53 gene are not detectable in human testicular tumors. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[63] H. Schmoll,et al. Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular‐cancer cell lines differing in their sensitivity to standard agents , 1994, International journal of cancer.
[64] A. de la Chapelle,et al. Oncogenes in human testicular cancer: DNA and RNA studies. , 1991, British Journal of Cancer.
[65] L. Martínez-Piñeiro,et al. Determination of the Percentage of Free Prostate–Specific Antigen Helps to Avoid Unnecessary Biopsies in Men with Normal Rectal Examinations and Total Prostate–Specific Antigen of 4–10 ng/ml , 2000, European Urology.
[66] Chunde Li,et al. Chromosomal Numerical Aberrations Detected by Fluorescence in situ Hybridization on Bladder Washings from Patients with Bladder Cancer , 2000, European Urology.
[67] Kazumi Suzuki,et al. Serum Anti–p53 Antibodies and p53 Protein Status in the Sera and Tumors from Bladder Cancer Patients , 2000, European Urology.
[68] P. Pollock,et al. Compilation of somatic mutations of the CDKN2 gene in human cancers: Non‐random distribution of base substitutions , 1996, Genes, chromosomes & cancer.
[69] F. Mostofi,et al. Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. , 1994, The Journal of urology.
[70] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[71] W. Jiang,et al. E‐cadherin and its associated protein catenins, cancer invasion and metastasis , 1996, The British journal of surgery.
[72] K. Dieckmann,et al. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] E. Mumperow,et al. Spermatic cord beta-human chorionic gonadotropin levels in seminoma and their clinical implications. , 1992, The Journal of urology.
[74] M. Mandalà,et al. Paradoxical Stimulation of Prolactin Secretion by L–Dopa in Metastatic Prostate Cancer and Its Possible Role in Prostate–Cancer–Related Hyperprolactinemia , 2000, European Urology.
[75] N. Skakkebæk. POSSIBLE CARCINOMA-IN-SITU OF THE TESTIS , 1972 .
[76] M. Skolnick,et al. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. , 1995, Oncogene.
[77] H. Rochefort,et al. Alterations and role of human cathepsin D in cancer metastasis. , 1996, Enzyme & protein.
[78] J. Serth,et al. Overexpression of the p53 oncoprotein in carcinoma in situ of the testis. , 1994, Pathology, research and practice.
[79] J. Bos,et al. Activated ras genes in human seminoma: evidence for tumor heterogeneity. , 1989, Oncogene.
[80] D. Harrison,et al. Natural disasters and man-made responses: are we protecting environmental health? , 1993, Environmental health perspectives.
[81] A. Levine,et al. A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation , 1996, Nature Medicine.
[82] H. Walt,et al. Isochromosome 12p in malignant testicular tumors. , 1985, Cancer genetics and cytogenetics.
[83] T. Strohmeyer,et al. Analysis of the DCC tumor suppressor gene in testicular germ cell tumors: mutations and loss of expression. , 1997, The Journal of urology.
[84] R. Smith,et al. Frequent loss of heterozygosity at 11p loci in testicular cancer. , 1995, The Journal of urology.
[85] I. Bodrogi,et al. Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins. , 1998, Anticancer research.
[86] J W Moul,et al. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. , 1994, The Journal of urology.